Hikma Pharmaceuticals (OTCMKTS:HKMPF) Hits New 1-Year High – What’s Next?

Posted by Linda Flegge on Feb 7th, 2025

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as high as $28.14 and last traded at $28.14, with a volume of 100 shares trading hands. The stock had previously closed at $26.64.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, December 10th.

Get Our Latest Analysis on Hikma Pharmaceuticals

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.98 and a current ratio of 1.66. The business’s 50-day moving average is $24.94 and its 200-day moving average is $24.98.

About Hikma Pharmaceuticals

(Get Free Report)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.